Latest News and Press Releases
Want to stay updated on the latest news?
-
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 +...
-
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft...
-
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM...
-
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDayManagement discussed financial position, milestones, and new opportunities presented by current market...
-
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatilityWith $24.2 million gross proceeds from its December 2021 IPO, ImmixBio...
-
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cellsImmixBio anticipates filing an IND for IMX-120 in 2023The...
-
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics...
-
Manufactured IMX-110 to be utilized in both clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 + BeiGene anti-PD-1...
-
IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune systemHistorically,...
-
100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trialIMX-110 is in clinical development as a monotherapy...